List view / Grid view
Progressing drug discovery projects to a stage that attracts commercial…
Progressing drug discovery projects to a stage that attracts commercial interest is a challenging endeavour, evidenced by the fact that only a small proportion of drug discovery projects are successfully progressed to such a stage. A major cause of this is the lack of comprehensive profiling of compounds prior to…
In this In-Depth Focus: the importance of characterising chemical starting…
In this In-Depth Focus: the importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays, and why do we have no effective treatments for osteoarthritis?
This article compares and contrasts a commonly used cell viability…
This article compares and contrasts a commonly used cell viability assay in manual and automated fashion and provides exemplar data from each scenario.
In this issue: how lab automation has accelerated pharmaceutical research…
In this issue: how lab automation has accelerated pharmaceutical research by simplifying operations, reducing manual tasks and increasing the efficiency, quality and reproducibility of results.
Neglected tropical diseases (NTD) affect more than one billion people…
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
A significant amount of selectivity and potency data originating from…
A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...
In this In-Depth Focus we look at using bioinformatics sequence…
In this In-Depth Focus we look at using bioinformatics sequence similarities to optimise repurposing activities; informatics infrastructure in neglected disease research, and machine learning for accelerating drug discovery.
In this In-Depth Focus we look at a pragmatic approach…
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
Drugs exert therapeutically meaningful effects if they bind with appropriate…
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
This in-depth focus looks at improving assay techniques to produce…
This in-depth focus looks at improving assay techniques to produce more detailed results using crystallography. It also covers some aspects of high-content screening assay development that are critical to successful implementation...
Included in this issue: The importance of industry partnerships; Calcilytics…
Included in this issue: The importance of industry partnerships; Calcilytics as potential novel therapeutic treatments to halt Alzheimer's disease; Accelerating neuroscience research with flow cytometry...
References Pal C, Papp B, Lazar V. Collateral sensitivity of…
12 July 2017 | By
References Pal C, Papp B, Lazar V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 2015;23:401-7. Guthrie R, Loebeck ME, Hillman MJ, Zgorzynski F. Tests for collateral sensitivity or cross resistance in bacterial mutants resistant to amethopterin or purine analogs. Cancer Res. 1958;18:319-34. Imamovic L, Sommer MO. Use of collateral sensitivity…
The screening of drug targets against compound libraries is now…
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Included in this Screening In-Depth Focus: Phenotypic and target-based screening;…
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Dr Sheraz Gul, Head of Assay Development and Screening at…
Dr Sheraz Gul, Head of Assay Development and Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology, answers questions on assay procedures...
